Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

Journal of Hypertension

Volumn 24, Issue 11, 2006, Pages 2285-2292

  Van Den Meiracker, Anton H ^a   Baggen, Rini G A ^b   Pauli, Sacha ^a   Lindemans, Anouk ^a   Vulto, Arnold G ^a   Poldermans, Don ^a   Boomsma, Frans ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IKAZIA HOSPITAL   (Netherlands)

Author keywords

Diabetes mellitus; Nephropathy; Proteinuria; Spironolactone

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; VALSARTAN;

ADD ON THERAPY; ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

EID: 33750274950     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000249708.44016.5c     Document Type: Article

References (32)

1. Rossing P. Promotion, prediction, and prevention of progression in diabetic nephropathy. Diabet Med 1998; 15:900-919.
2. King H, Aubert R, Herman W. Global burden of diabetes 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care 1998; 21:1414-1431.
3. Parving HH. Diabetic nephropathy: Prevention and treatment. Kidney Int 2001; 60:2041-2055.
4. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346:1145-1151.
5. American Diabetes Association. Management of dyslipidemia in aldults with diabetes. Diabetes Care 2003; 26 (Suppl 1):S83-S86.
6. Remuzzi G, Ruggenenti P, Percio N. Chronic renal diseases: renal protective benefits of renin-angiotensin system inhibition. Ann Int Med 2002; 136:604-615.
7. Keane WF, Brenner BM, De Zeeuw, Grunfeld JP, McGill J, Mitch WE, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int 2003; 63:1499-1507.
8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
9. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to diabetes type 2. N Engl J Med 2001; 345:851-860.
10. Brenner BM, Cooper MA, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:851-860.
11. De Zeeuw D, Remuzzi G, Parving H-H, Keane WF, Zhang Z, Stahifar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65:2309-2320.
12. Rocha R, Chander PN, Kavita K, Zuckerman A, Stier CT. Role of aldosterone in renal vascular injury in stroke prone hypertensive rats. Hypertension 1999; 33:232-237.
13. Greene E, Kren S, Hostetter TH. Role of aldosterone in the remmant kidney model in the rat. J Clin Invest 1996; 98:1063-1068.
14. Epstein M. Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. Am J Kidney Dis 2001; 37:677-688.
15. Rocha R, Chander PN, Kavita K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke prone hypertensive rats. Hypertension 1998; 31:451-458.
16. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibais S. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004; 66:1493-1502.
17. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41:64-68.
18. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving H-H. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47:1936-1939.
19. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345:925-926.
20. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled study. Am J Kidney Dis 2005; 46:45-51.
21. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care 2005; 28:2106-2112.
22. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18:44-49.
23. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
24. Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996; 32:266-273.
25. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcaye C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33:981-986.
26. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13:1682-1685.
27. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induced renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63:1791-1800.
28. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51:793-797.
29. Bakris GL, Wier MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause of concern? Arch Intern Med 2000; 160:685-693.
30. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. The randomized aldactone evaluation study [RALES]. Am J Cardiol 1996; 78:902-907.
31. Svensson M, Gustafsson F, Galtius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004; 10:297-303.
32. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351:543-551.